TY - STD TI - Kidney Disease. Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009(113):S1–130. ID - ref1 ER - TY - JOUR AU - Block, G. A. AU - Klassen, P. S. AU - Lazarus, J. M. AU - Ofsthun, N. AU - Lowrie, E. G. AU - Chertow, G. M. PY - 2004 DA - 2004// TI - Mineral metabolism, mortality, and morbidity in maintenance hemodialysis JO - J Am Soc Nephrol VL - 15 UR - https://doi.org/10.1097/01.ASN.0000133041.27682.A2 DO - 10.1097/01.ASN.0000133041.27682.A2 ID - Block2004 ER - TY - JOUR AU - Melamed, M. L. AU - Eustace, J. A. AU - Plantinga, L. PY - 2006 DA - 2006// TI - Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study JO - Kidney Int VL - 70 UR - https://doi.org/10.1038/sj.ki.5001542 DO - 10.1038/sj.ki.5001542 ID - Melamed2006 ER - TY - JOUR AU - Young, E. W. AU - Albert, J. M. AU - Satayathum, S. PY - 2005 DA - 2005// TI - Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study JO - Kidney Int VL - 67 UR - https://doi.org/10.1111/j.1523-1755.2005.00185.x DO - 10.1111/j.1523-1755.2005.00185.x ID - Young2005 ER - TY - JOUR AU - Kalantar-Zadeh, K. AU - Kuwae, N. AU - Regidor, D. L. PY - 2006 DA - 2006// TI - Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients JO - Kidney Int VL - 70 UR - https://doi.org/10.1038/sj.ki.5001514 DO - 10.1038/sj.ki.5001514 ID - Kalantar-Zadeh2006 ER - TY - JOUR AU - Ganesh, S. K. AU - Stack, A. G. AU - Levin, N. W. AU - Hulbert-Shearon, T. AU - Port, F. K. PY - 2001 DA - 2001// TI - Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients JO - J Am Soc Nephrol VL - 12 ID - Ganesh2001 ER - TY - JOUR AU - Tentori, F. AU - Blayney, M. J. AU - Albert, J. M. PY - 2008 DA - 2008// TI - Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS) JO - Am J Kidney Dis VL - 52 UR - https://doi.org/10.1053/j.ajkd.2008.03.020 DO - 10.1053/j.ajkd.2008.03.020 ID - Tentori2008 ER - TY - JOUR AU - Teng, M. AU - Wolf, M. AU - Lowrie, E. AU - Ofsthun, N. AU - Lazarus, J. M. AU - Thadhani, R. PY - 2003 DA - 2003// TI - Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMoa022536 DO - 10.1056/NEJMoa022536 ID - Teng2003 ER - TY - JOUR AU - Cheng, J. AU - Zhang, W. AU - Zhang, X. AU - Li, X. AU - Chen, J. PY - 2012 DA - 2012// TI - Efficacy and Safety of Paricalcitol Therapy for Chronic Kidney Disease: A Meta-Analysis JO - Clin J Am Soc Nephrol VL - 7 UR - https://doi.org/10.2215/CJN.03000311 DO - 10.2215/CJN.03000311 ID - Cheng2012 ER - TY - STD TI - Han T, Rong G, Quan D, et al. Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. Biomed Res Int. 2013;2013:–320560. ID - ref10 ER - TY - JOUR AU - Li, X. -. H. AU - Feng, L. AU - Yang, Z. -. H. AU - Liao, Y. -. H. PY - 2015 DA - 2015// TI - Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis JO - Nephrology VL - 20 UR - https://doi.org/10.1111/nep.12505 DO - 10.1111/nep.12505 ID - Li2015 ER - TY - STD TI - Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GFM. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2009;4 ID - ref12 ER - TY - STD TI - Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GFM. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;4 ID - ref13 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. AU - Grp, P. PY - 2010 DA - 2010// TI - Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement JO - Int J Surg VL - 8 UR - https://doi.org/10.1016/j.ijsu.2010.02.007 DO - 10.1016/j.ijsu.2010.02.007 ID - Moher2010 ER - TY - JOUR AU - Stedman, M. R. AU - Curtin, F. AU - Elbourne, D. R. AU - Kesselheim, A. S. AU - Brookhart, M. A. PY - 2011 DA - 2011// TI - Meta-analyses involving cross-over trials: methodological issues JO - Int J Epidemiol VL - 40 UR - https://doi.org/10.1093/ije/dyp345 DO - 10.1093/ije/dyp345 ID - Stedman2011 ER - TY - JOUR AU - Moher, D. AU - Pham, B. AU - Jones, A. PY - 1998 DA - 1998// TI - Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? JO - Lancet VL - 352 UR - https://doi.org/10.1016/S0140-6736(98)01085-X DO - 10.1016/S0140-6736(98)01085-X ID - Moher1998 ER - TY - JOUR AU - Jadad, A. R. AU - Moore, R. A. AU - Carroll, D. PY - 1996 DA - 1996// TI - Assessing the quality of reports of randomized clinical trials: is blinding necessary? JO - Control Clin Trials VL - 17 UR - https://doi.org/10.1016/0197-2456(95)00134-4 DO - 10.1016/0197-2456(95)00134-4 ID - Jadad1996 ER - TY - JOUR AU - Higgins, J. P. AU - Thompson, S. G. AU - Deeks, J. J. AU - Altman, D. G. PY - 2003 DA - 2003// TI - Measuring inconsistency in meta-analyses JO - BMJ VL - 327 UR - https://doi.org/10.1136/bmj.327.7414.557 DO - 10.1136/bmj.327.7414.557 ID - Higgins2003 ER - TY - JOUR AU - Begg, C. B. AU - Mazumdar, M. PY - 1994 DA - 1994// TI - Operating characteristics of a rank correlation test for publication bias JO - Biometrics VL - 50 UR - https://doi.org/10.2307/2533446 DO - 10.2307/2533446 ID - Begg1994 ER - TY - JOUR AU - Egger, M. AU - Davey Smith, G. AU - Schneider, M. AU - Minder, C. PY - 1997 DA - 1997// TI - Bias in meta-analysis detected by a simple, graphical test JO - BMJ VL - 315 UR - https://doi.org/10.1136/bmj.315.7109.629 DO - 10.1136/bmj.315.7109.629 ID - Egger1997 ER - TY - JOUR AU - Akizawa, T. AU - Akiba, T. AU - Hirakata, H. PY - 2015 DA - 2015// TI - Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism JO - Ther Apher Dial VL - 19 UR - https://doi.org/10.1111/1744-9987.12242 DO - 10.1111/1744-9987.12242 ID - Akizawa2015 ER - TY - JOUR AU - Jamaluddin, E. J. AU - Gafor, A. H. AU - Yean, L. C. PY - 2014 DA - 2014// TI - Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism JO - Clin Exp Nephrol VL - 18 UR - https://doi.org/10.1007/s10157-013-0844-2 DO - 10.1007/s10157-013-0844-2 ID - Jamaluddin2014 ER - TY - JOUR AU - Ong, L. M. AU - Narayanan, P. AU - Goh, H. K. PY - 2013 DA - 2013// TI - Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism JO - Nephrology VL - 18 UR - https://doi.org/10.1111/nep.12029 DO - 10.1111/nep.12029 ID - Ong2013 ER - TY - JOUR AU - Hansen, D. AU - Rasmussen, K. AU - Danielsen, H. PY - 2011 DA - 2011// TI - No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial JO - Kidney Int VL - 80 UR - https://doi.org/10.1038/ki.2011.226 DO - 10.1038/ki.2011.226 ID - Hansen2011 ER - TY - JOUR AU - Lund, R. J. AU - Andress, D. L. AU - Amdahl, M. AU - Williams, L. A. AU - Heaney, R. P. PY - 2010 DA - 2010// TI - Differential Effects of Paricalcitol and Calcitriol on Intestinal Calcium Absorption in Hemodialysis Patients JO - Am J Nephrol VL - 31 UR - https://doi.org/10.1159/000266204 DO - 10.1159/000266204 ID - Lund2010 ER - TY - JOUR AU - Abdul Gafor, A. H. AU - Saidin, R. AU - Loo, C. Y. PY - 2009 DA - 2009// TI - Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism JO - Nephrology VL - 14 UR - https://doi.org/10.1111/j.1440-1797.2008.01058.x DO - 10.1111/j.1440-1797.2008.01058.x ID - Abdul Gafor2009 ER - TY - JOUR AU - Sprague, S. M. AU - Llach, F. AU - Amdahl, M. AU - Taccetta, C. AU - Batlle, D. PY - 2003 DA - 2003// TI - Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism JO - Kidney Int VL - 63 UR - https://doi.org/10.1046/j.1523-1755.2003.00878.x DO - 10.1046/j.1523-1755.2003.00878.x ID - Sprague2003 ER - TY - JOUR AU - Veceric-Haler, Z. AU - Romozi, K. AU - Antonic, M. PY - 2016 DA - 2016// TI - Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population JO - Ther Apher Dial VL - 20 UR - https://doi.org/10.1111/1744-9987.12434 DO - 10.1111/1744-9987.12434 ID - Veceric-Haler2016 ER - TY - JOUR AU - Duranton, F. AU - Rodriguez-Ortiz, M. E. AU - Duny, Y. AU - Rodriguez, M. AU - Daures, J. P. AU - Argiles, A. PY - 2013 DA - 2013// TI - Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis JO - Am J Nephrol VL - 37 UR - https://doi.org/10.1159/000346846 DO - 10.1159/000346846 ID - Duranton2013 ER - TY - JOUR AU - Navaneethan, S. D. AU - Palmer, S. C. AU - Craig, J. C. AU - Elder, G. J. AU - Strippoli, G. F. PY - 2009 DA - 2009// TI - Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials JO - Am J Kidney Dis VL - 54 UR - https://doi.org/10.1053/j.ajkd.2009.06.004 DO - 10.1053/j.ajkd.2009.06.004 ID - Navaneethan2009 ER - TY - JOUR AU - Miller, J. E. AU - Molnar, M. Z. AU - Kovesdy, C. P. PY - 2012 DA - 2012// TI - Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis JO - Pharmacoepidemiol Drug Saf VL - 21 UR - https://doi.org/10.1002/pds.3349 DO - 10.1002/pds.3349 ID - Miller2012 ER - TY - JOUR AU - Silver, J. AU - Naveh-Many, T. PY - 2013 DA - 2013// TI - FGF-23 and secondary hyperparathyroidism in chronic kidney disease JO - Nat Rev Nephrol VL - 9 UR - https://doi.org/10.1038/nrneph.2013.147 DO - 10.1038/nrneph.2013.147 ID - Silver2013 ER - TY - JOUR AU - Hu, M. C. AU - Shiizaki, K. AU - Kuro-o, M. AU - Moe, O. W. PY - 2013 DA - 2013// TI - Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism JO - Annu Rev Physiol VL - 75 UR - https://doi.org/10.1146/annurev-physiol-030212-183727 DO - 10.1146/annurev-physiol-030212-183727 ID - Hu2013 ER - TY - JOUR AU - Gutierrez, O. AU - Isakova, T. AU - Rhee, E. PY - 2005 DA - 2005// TI - Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease JO - J Am Soc Nephrol VL - 16 UR - https://doi.org/10.1681/ASN.2005010052 DO - 10.1681/ASN.2005010052 ID - Gutierrez2005 ER - TY - JOUR AU - Isakova, T. AU - Wahl, P. AU - Vargas, G. S. PY - 2011 DA - 2011// TI - Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease JO - Kidney Int VL - 79 UR - https://doi.org/10.1038/ki.2011.47 DO - 10.1038/ki.2011.47 ID - Isakova2011 ER - TY - JOUR AU - Hansen, D. AU - Rasmussen, K. AU - Pedersen, S. M. AU - Rasmussen, L. M. AU - Brandi, L. PY - 2012 DA - 2012// TI - Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol JO - Nephrol Dial Transplant VL - 27 UR - https://doi.org/10.1093/ndt/gfr668 DO - 10.1093/ndt/gfr668 ID - Hansen2012 ER - TY - STD TI - Cai P, Tang X, Qin W, Ji L, Li Z. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol. 2016; ID - ref37 ER - TY - JOUR AU - Palmer, S. C. AU - McGregor, D. O. AU - Macaskill, P. AU - Craig, J. C. AU - Elder, G. J. AU - Strippoli, G. F. M. PY - 2007 DA - 2007// TI - Meta-analysis: Vitamin D compounds in chronic kidney disease JO - Ann Intern Med VL - 147 UR - https://doi.org/10.7326/0003-4819-147-12-200712180-00004 DO - 10.7326/0003-4819-147-12-200712180-00004 ID - Palmer2007 ER - TY - JOUR AU - Uhlig, K. PY - 2011 DA - 2011// TI - What should a guideline panel do when evidence is inconclusive? The case of treatments for CKD-mineral and bone disorder (CKD-MBD) JO - Am J Kidney Dis VL - 58 UR - https://doi.org/10.1053/j.ajkd.2011.08.001 DO - 10.1053/j.ajkd.2011.08.001 ID - Uhlig2011 ER - TY - JOUR AU - Palmer, S. C. AU - Hayen, A. AU - Macaskill, P. PY - 2011 DA - 2011// TI - Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis JO - JAMA VL - 305 UR - https://doi.org/10.1001/jama.2011.308 DO - 10.1001/jama.2011.308 ID - Palmer2011 ER -